gebasaxturev

AXP000123.1 · Oncolytic virus

Platform
coxsackievirus A21 (Kuykendall strain, wild-type)
Originator
Viralytics
Sponsor
Merck Sharp & Dohme

Names

NameTypeSource
gebasaxturevpreferred name, INNcurator, ncit
CAVATAKbrandncit
V937codencit
CVA21 ambiguoussynonymncit

Virus

Role
Oncolytic
Family
Picornaviridae
Virus
coxsackievirus A21 (NCBI Taxonomy 12069)
Strain
Kuykendall
Replication
replicating
Modifications
none (wild-type isolate)
Route
intratumoral, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C61493

Approvals

No regulatory approval recorded.

Clinical trials (14)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04521621A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)TerminatedPhase 1/22020-10-282023-07-2576Neoplasm Metastasis
NCT04303169Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/22020-06-262025-09-24146Melanoma
NCT04152863Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedPhase 22020-06-052023-07-1285Advanced/Metastatic Melanoma
NCT03408587CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedPhase 12018-01-292019-05-2211Liver Metastases; Uveal Melanoma
NCT02824965Pembrolizumab + CVA21 in Advanced NSCLCUnknownPhase 12017-08-092021-07-0111Non-Small Cell Lung Cancer
NCT02565992Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedPhase 12015-12-172019-11-0436Melanoma
NCT02307149Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedPhase 12015-05-052019-11-0550Melanoma
NCT02316171CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)CompletedPhase 12015-01-162016-03-1416Non-muscle Invasive Bladder Cancer
NCT02043665CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)CompletedPhase 12013-12-182020-01-1085Bladder Cancer; Non-small Cell Lung Cancer
NCT01636882CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)CompletedPhase 22012-07-032016-04-0616Melanoma
NCT01227551A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )CompletedPhase 22011-12-292016-04-0657Malignant Melanoma
NCT00832559A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)TerminatedPhase 12009-01-272011-07-284Head and Neck Cancer
NCT00636558Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)CompletedPhase 12008-02-292012-01-128Breast Cancer; Melanoma; Prostate Cancer
NCT00438009A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)CompletedPhase 12007-05-162009-08-289Stage IV Melanoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42190314Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.ESMO open2026name in abstract: gebasaxturev
PMID 39775043Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.Nature medicine2025cited by trial NCT04303169
PMID 36445410A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.Cancer immunology, immunotherapy : CII2023cited by trial NCT02565992
PMID 36651961Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.Journal of cancer research and clinical oncology2023cited by trial NCT03408587
PMID 36669791Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.Journal for immunotherapy of cancer2023cited by trial NCT02043665
PMID 35387488Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification.Human gene therapy2022cited by trial NCT04152863
PMID 36564126Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.Journal for immunotherapy of cancer2022cited by trial NCT02307149
PMID 34464163Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2021cited by trial NCT01227551
PMID 31273010Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2019cited by trial NCT02316171
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 40932352Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: CVA21

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40750724Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in Combination.Clinical pharmacokinetics2025name in title: V937
PMID 38745749Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.Molecular therapy. Oncology2024name in title: V937
PMID 39037559Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab.Clinical pharmacology and therapeutics2024name in title: V937
PMID 39207089Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy.Experimental dermatology2024name in title: V937
PMID 36299168Oncolytic virus preclinical toxicology studies.Journal of applied toxicology : JAT2023name in abstract: CAVATAK
PMID 37170933Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.Clinical pharmacology and therapeutics2023name in title: V937
PMID 37771727A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.Frontiers in pharmacology2023name in title: V937
PMID 34277838Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine2021name in abstract: CAVATAK
PMID 34366859Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.Frontiers in pharmacology2021name in title: V937
PMID 32162802Intratumoral Immunotherapy-Update 2019.The oncologist2020name in abstract: CAVATAK
PMID 30261620The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.Cancers2018name in abstract: CAVATAK
PMID 30190880Intralesional treatment for advanced melanoma: what's on the horizon?Melanoma management2016name in abstract: CAVATAK
PMID 24301265Intralesional immunotherapy for melanoma.Journal of surgical oncology2014name in abstract: CAVATAK
Unconfirmed matches (7)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 42625927Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.Iranian journal of microbiology2026name in abstract: V937
PMID 40328704[Preparation and antitumor activity characterization of oncolytic nanoparticles encapsulating CVA21].Sheng wu gong cheng xue bao = Chinese journal of biotechnology2025name in title: CVA21
PMID 35024440SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.Molecular therapy oncolytics2022name in abstract: V937
PMID 28025712A cluster of coxsackievirus A21 associated acute respiratory illness: the evidence of efficient transmission of CVA21.Archives of virology2017name in title: CVA21
PMID 24695547The evolution of Vp1 gene in enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.PloS one2014name in title: CVA21
PMID 24722726Recombination in the evolution of enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.PloS one2014name in title: CVA21
PMID 12572466[Inhibition of 5 compounds from Bidens bipinnata on leukemia cells in vitro].Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials1997name in abstract: V937

Notes

Unmodified coxsackievirus A21, brand CAVATAK; renamed V937 after Merck acquired Viralytics in 2018. Merck has since stopped the programme. INN gebasaxturev.

How to cite

gebasaxturev (AXP000123.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000123.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.